Gujarat Themis Biosyn FY26 Income ₹168.25 Cr, PAT ₹46.68 Cr

Gujarat Themis Biosyn Limited reported its financial results for the fiscal year ended March 31, 2026. The company achieved a total income of ₹168.25 crores, with an EBITDA of ₹75.53 crores and a Profit After Tax (PAT) of ₹46.68 crores. Key developments during the year included a significant expansion of fermentation capacity, operationalization of a new API facility, and advancements in R&D. The company also announced strategic inorganic growth initiatives, including the acquisition of 13 global brands from Sanofi and the incorporation of a wholly-owned subsidiary in Japan, Themis Biosyn Japan Limited, along with the acquisition of MicroBiopharm Japan Co. Ltd. These moves aim to strengthen its market position, expand its product portfolio, and increase its global presence.